Principia Biopharma

Principia Biopharma is committed to bringing transformative therapies to patients with severe immune-mediated diseases by changing the way small molecules are developed. Their mission is to create first-class drugs that meet unmet medical needs by revolutionizing the design approach of small molecule drugs. They are a late-stage biopharmaceutical company focused on developing next-generation immunomodulatory therapies, which could potentially transform the treatment paradigm for underserved patients suffering from immune-mediated diseases. Leveraging their proprietary and unique Tailored Covalent Drug Design® platform, they have developed reversible covalent and irreversible covalent small molecule drugs that bind with high specificity to targets associated with immune system disorders in the body.